Explore the Agenda
Research Breakthroughs Day
Monday, October 26
Pipeline Progression Day 1
Tuesday, October 27
Pipeline Progression Day 2
Wednesday, October 28
Future Technologies & Innovations Day
Thursday, October 29
7:30 am Check In & Refreshments
8:20 am Chair’s Opening Remarks
Accelerating Induced Proximity Innovation Through Strategic Partnerships, Investment & Data-Driven Decision Making to Power the Future of Drug Development
8:30 am Session Details to be Announced
9:00 am BTX-9341, a First-in-Class, Potent & Selective CDK4/6 Degrader, for the Treatment of Advanced/Metastatic HR+/HER2- Breast Cancer Post-CDK4/6 Inhibitor Therapy – Latest from the Clinic
- BTX-9341-101 Phase 1 study design and patient population
- Safety/tolerability and PK/PD profile of BTX-9341 as monotherapy and in combination with fulvestrant
- Promising clinical activity in a heavily pre-treated patient population post-CDK4/6 inhibitor therapies with high disease burden
9:30 am Panel Discussion: Shaping Investment in Induced Proximity: Insights to Accelerate Development & Secure Funding
- Exploring the data, targets, and indications investors are prioritizing to support next-generation induced proximity therapeutics
- Discussing funding strategies for early-stage companies, including milestones needed to secure investment and attract pharmaceutical partnerships
- Evaluating how scientific innovation and emerging modalities influence investor confidence and the types of assets and platforms likely to attract investor interest
10:15 am Session Details to be Announced
- Promega
10:45 am Morning Break & Networking Time
Track A: Discovery
Deciphering the Biology of Ternary Complexes Using Structural & Biophysical Tools to Drive the Discovery of Effective Induced Proximity Therapeutics
11:30 am Proteomics & AI Platform Maps Degrader-Induced Ternary Complex Diversity to Enable Rational Degrader Design
CTO, Protai
- Demonstrating how the AIMS (AI + MS) platform integrates AI modeling and structural proteomics to map protein interactions and inform degrader design
- Showcasing lead optimization strategies to enhance the efficacy, selectivity, and rational design of molecular glues and degraders
- Presenting preclinical results from Protai’s KAT6a selective degrader program as a case study of AIMS-enabled design
12:00 pm Session Details to be Announced
- Ice Biosciences
12:30 pm Potent & Selective TBK1 Molecular Glue Degraders with Non-Canonical Degron Binding Mode
Professor of Chemical Biology & Director of the Centre for Protein Degradation, Institute of Cancer Research
- Design and screening of our next generation cereblon-focused molecular glue library by highthroughput proteomics that led to the discovery of TBK1 molecular glue degraders
- Optimisation and structural characterisation of MGDs forming non-canonical ternary complex with TBK1 and CRBN
- Pharmacological profiling demonstrating high potency in multiple cancer models in vitro and in vivo
1:00 pm Session Details to be Announced
- Ajinimoto Biopharma Services
1:30 pm Lunch Break & Networking Time
Transitioning from Serendipitous Discovery to Rational Design to Enable Intentional, Efficient Development of Robust Induced Proximity Therapies
2:15 pm Linking Molecular Glue Binding Kinetics to Functional Performance Through Quantitative Modeling
Senior Director, Oncology Chemistry, AstraZeneca
- Despite recent progress, molecular glue discovery remains highly challenging, partly due to limited quantitative understanding of how binding kinetics and ternary complex formation translate into cellular function
- We developed and validated a mechanistic modeling framework that links molecular glue binding kinetics to functional outcomes for both stabilizers and degraders across biochemical and cellular systems
- Representative examples illustrate how binding kinetics and key system level factors jointly inform rational molecular glue discovery, optimization, and decision making
2:45 pm Optimizing Novel Heterobifunctional Degraders – An Update
Head, Candidate Delivery, Engineered Small Molecules, Astellas Pharma
- Overview of Astellas’ TPD approach to overcome undruggable targets
- Updating next-generation degrader candidates
- Emerging DAC approaches to deliver TPD molecules to tumor tissues
3:15 pm Session Details to be Announced
- HitChem
3:25 pm Afternoon Break & Networking Time
Track B: Pre-Clinical Development
Track C: Translational & Clinical Development
Pushing the Boundaries of Induced Proximity with Novel Modalities & Targets to Expand the Druggable Proteome & Unlock New Treatment Strategies Across More Indications
4:00 pm Unlocking the FBOX: Building an End-to-End Discovery engine for Molecular Glues Using a Novel E3 Ligase
- We established an CUL1 E3 ligase not previously exploited for TPD starting from a dedicated DNA encoded library (DEL) screen
- Hit ligands were systematically optimized for physicochemical properties and converted into a focused, glue-like compound library purpose-built for downstream target profiling
- Affinity-enrichment mass spectrometry mapping of glueable targets revealed a target space which is distinct from established ligases such as CRBN
4:30 pm Molecular Glue Degrader–Induced Co-Degradation of Mutant KRAS & CRAF Drives In Vivo Responses
- Discovery and optimization of a molecular glue degrader targeting mutant KRAS and CRAF
- Mechanism of action and structural basis of induced co-degradation
- In vivo efficacy and therapeutic potential in KRAS-mutant models
5:00 pm Identification of First-in-Class KAT6A Degraders Leading to Potent & KAT6A-Selective Oral Development Candidate PRT13722
- Discovery of KAT6A degrader compounds
- Characterization and proof-of-concept studies with KAT6A degraders
- Preclinical profile of KAT6A-selective development candidate PRT13722